Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KSD 101

Drug Profile

KSD 101

Alternative Names: KSD-101

Latest Information Update: 19 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kousai Bio
  • Class Antineoplastics; Cancer vaccines; Dendritic cell vaccines; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Haematological malignancies
  • Phase 0 Lymphoma; Nasopharyngeal cancer

Most Recent Events

  • 19 Apr 2024 Kousai Bio in collaboration with Sun Yat-sen University plans a phase 0 trial for Nasopharyngeal cancer (Locally recurrent, Metastatic disease, Second-line therapy or greater) in China (SC) in May 2024(NCT06370026)
  • 09 Dec 2023 Efficacy, immunogenicity and adverse event data from phase I trial in EBV-associated Haematologic Neoplasms presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
  • 04 Dec 2023 Phase-0 for Nasopharyngeal cancer (Locally recurrent, Metastatic disease) in China (SC) (NCT06097793)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top